Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease
Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.
The Food and Drug Administration (FDA) has granted fast track designation to BR55, an emerging molecular ultrasound contrast agent, for the diagnosis of active bowel inflammation in patients with Crohn’s disease.
Targeting the vascular endothelial growth factor receptor 2 (VEGFR2), the injection of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) achieved a 95 percent accuracy in revealing active bowel inflammation in patients with Crohn’s disease in phase 2 studies, according to Bracco Imaging, the developer of the ultrasound contrast agent.
The company maintained that the use of BR55 to detect angiogenesis through non-invasive, radiation-free ultrasound imaging may enhance monitoring and facilitate timely treatment in this patient population.
“The FDA fast track process is aimed at improving the management of patients with serious conditions and filling an unmet medical need, such as the accurate monitoring of disease activity in patients with Crohn's disease,” noted Alberto Spinazzi, M.D., the chief medical and regulatory officer for the Bracco Imaging Group. “This fast track designation supports our goal to get BR55 to the patient earlier and more efficiently."
Bracco Imaging noted that the efficacy and safety of BR55 will be evaluated in forthcoming multicenter, multinational phase 3 studies.
Recent Videos
Related Content
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025Podcast
In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Article
Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025Article
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
